NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer, will present a company overview at the Q4 Investor Summit. The company will be available for 1-on-1 meetings throughout the day in addition to its presentation.

Event: Q4 Investor Summit
Presentation Time: 1:00pm - 1:30pm ET
Location: https://www.webcaster4.com/Webcast/Page/3075/51591

• The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.

• Take a deep dive with the best Investors in MicroCap

• Live Q & A

• Complimentary to Qualified Investors. Please REGISTER HERE.

About Immunic, Inc.
Immunic, Inc. (NASDAQ:IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Founded in 2015.

CONTACT:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group

SOURCE: Immunic